TY  - JOUR
AU  - Schwarze, Benedikt
AU  - Jelača, Sanja
AU  - Welcke, Linda
AU  - Maksimović-Ivanić, Danijela
AU  - Mijatović, Sanja
AU  - Hey-Hawkins, Evamarie
PY  - 2019
UR  - https://onlinelibrary.wiley.com/doi/abs/10.1002/cmdc.201900554
UR  - https://radar.ibiss.bg.ac.rs/handle/123456789/3531
AB  - Investigations on the antitumor activity of metallacarboranes are sparse in the literature and limited to a handful of ruthena- and molybdacarboranes. In this study, the molybdacarborane fragment [3-(CO)2 -closo-3,1,2-MoC2 B9 H11 ] was combined with a vector molecule, inspired by the well-known drug tamoxifen or 4,4'-dihydroxytamoxifen (TAM-diOH). The molybdacarborane derivative [3,3-{4-[1,1-bis(4-hydroxyphenyl)but-1-en-2-yl]-2,2'-bipyridine-κ2 N,N'}-3-(CO)2 -closo-3,1,2-MoC2 B9 H11 ] (10), as well as the ligand itself 4-[1,1-bis(4-hydroxyphenyl)but-1-en-2-yl]-2,2'-bipyridine (6) showed cytotoxic activities in the low micromolar range against breast adenocarcinoma (MDA-MB-231, MDA-MB-361 and MCF-7), human glioblastoma (LN-229) and human glioma (U-251) cell lines. In addition, compounds 6 and 10 were found to induce senescence and cytodestructive autophagy, lower ROS/RNS levels, but only the molybdacarborane 10 induced a strong increase of nitric oxide (NO) concentration in the MCF-7 cells.
T2  - ChemMedChem
T1  - 2,2'-Bipyridine-Modified Tamoxifen: A Versatile Vector for Molybdacarboranes.
IS  - 24
VL  - 14
DO  - 10.1002/cmdc.201900554
SP  - 2075
EP  - 2083
ER  - 

@article{
author = "Schwarze, Benedikt and Jelača, Sanja and Welcke, Linda and Maksimović-Ivanić, Danijela and Mijatović, Sanja and Hey-Hawkins, Evamarie",
year = "2019",
abstract = "Investigations on the antitumor activity of metallacarboranes are sparse in the literature and limited to a handful of ruthena- and molybdacarboranes. In this study, the molybdacarborane fragment [3-(CO)2 -closo-3,1,2-MoC2 B9 H11 ] was combined with a vector molecule, inspired by the well-known drug tamoxifen or 4,4'-dihydroxytamoxifen (TAM-diOH). The molybdacarborane derivative [3,3-{4-[1,1-bis(4-hydroxyphenyl)but-1-en-2-yl]-2,2'-bipyridine-κ2 N,N'}-3-(CO)2 -closo-3,1,2-MoC2 B9 H11 ] (10), as well as the ligand itself 4-[1,1-bis(4-hydroxyphenyl)but-1-en-2-yl]-2,2'-bipyridine (6) showed cytotoxic activities in the low micromolar range against breast adenocarcinoma (MDA-MB-231, MDA-MB-361 and MCF-7), human glioblastoma (LN-229) and human glioma (U-251) cell lines. In addition, compounds 6 and 10 were found to induce senescence and cytodestructive autophagy, lower ROS/RNS levels, but only the molybdacarborane 10 induced a strong increase of nitric oxide (NO) concentration in the MCF-7 cells.",
journal = "ChemMedChem",
title = "2,2'-Bipyridine-Modified Tamoxifen: A Versatile Vector for Molybdacarboranes.",
number = "24",
volume = "14",
doi = "10.1002/cmdc.201900554",
pages = "2075-2083"
}

Schwarze, B., Jelača, S., Welcke, L., Maksimović-Ivanić, D., Mijatović, S.,& Hey-Hawkins, E.. (2019). 2,2'-Bipyridine-Modified Tamoxifen: A Versatile Vector for Molybdacarboranes.. in ChemMedChem, 14(24), 2075-2083.
https://doi.org/10.1002/cmdc.201900554

Schwarze B, Jelača S, Welcke L, Maksimović-Ivanić D, Mijatović S, Hey-Hawkins E. 2,2'-Bipyridine-Modified Tamoxifen: A Versatile Vector for Molybdacarboranes.. in ChemMedChem. 2019;14(24):2075-2083.
doi:10.1002/cmdc.201900554 .

Schwarze, Benedikt, Jelača, Sanja, Welcke, Linda, Maksimović-Ivanić, Danijela, Mijatović, Sanja, Hey-Hawkins, Evamarie, "2,2'-Bipyridine-Modified Tamoxifen: A Versatile Vector for Molybdacarboranes." in ChemMedChem, 14, no. 24 (2019):2075-2083,
https://doi.org/10.1002/cmdc.201900554 . .

TY  - JOUR
AU  - Kuhnert, Robert
AU  - Sárosi, Menyhárt-Botond
AU  - George, Sven
AU  - Lönnecke, Peter
AU  - Hofmann, Bettina
AU  - Steinhilber, Dieter
AU  - Murganić, Blagoje
AU  - Mijatović, Sanja
AU  - Maksimović-Ivanić, Danijela
AU  - Hey-Hawkins, Evamarie
PY  - 2017
UR  - http://doi.wiley.com/10.1002/cmdc.201700309
UR  - https://radar.ibiss.bg.ac.rs/handle/123456789/2789
AB  - The progression of cancer is accelerated by increased proliferation, angiogenesis, and inflammation. These processes are mediated by leukotrienes. Several cancer cell lines overexpress 5-lipoxygenase, an enzyme that converts arachidonic acid into leukotrienes. An early inhibitor of the 5-lipoxygenase pathway is Rev-5901, which, however, lacks in invivo efficacy, as it is rapidly metabolized. We investigated the introduction of carboranes as highly hydrophobic and metabolically stable pharmacophores into lipoxygenase inhibitors. Carboranes are icosahedral boron clusters that are remarkably stable and used to increase the metabolic stability of unstable pharmaceutics without changing their biological activity. By introduction of meta-carborane into Rev-5901, the first carborane-based inhibitor of the 5-lipoxygenase pathway was obtained. We report the synthesis and inhibitory and cytotoxic behavior of these compounds toward several melanoma and colon cancer cell lines and their related anticancer mechanisms.
T2  - ChemMedChem
T1  - CarbORev-5901: The First Carborane-Based Inhibitor of the 5-Lipoxygenase Pathway
IS  - 13
VL  - 12
DO  - 10.1002/cmdc.201700309
SP  - 1081
EP  - 1086
ER  - 

@article{
author = "Kuhnert, Robert and Sárosi, Menyhárt-Botond and George, Sven and Lönnecke, Peter and Hofmann, Bettina and Steinhilber, Dieter and Murganić, Blagoje and Mijatović, Sanja and Maksimović-Ivanić, Danijela and Hey-Hawkins, Evamarie",
year = "2017",
abstract = "The progression of cancer is accelerated by increased proliferation, angiogenesis, and inflammation. These processes are mediated by leukotrienes. Several cancer cell lines overexpress 5-lipoxygenase, an enzyme that converts arachidonic acid into leukotrienes. An early inhibitor of the 5-lipoxygenase pathway is Rev-5901, which, however, lacks in invivo efficacy, as it is rapidly metabolized. We investigated the introduction of carboranes as highly hydrophobic and metabolically stable pharmacophores into lipoxygenase inhibitors. Carboranes are icosahedral boron clusters that are remarkably stable and used to increase the metabolic stability of unstable pharmaceutics without changing their biological activity. By introduction of meta-carborane into Rev-5901, the first carborane-based inhibitor of the 5-lipoxygenase pathway was obtained. We report the synthesis and inhibitory and cytotoxic behavior of these compounds toward several melanoma and colon cancer cell lines and their related anticancer mechanisms.",
journal = "ChemMedChem",
title = "CarbORev-5901: The First Carborane-Based Inhibitor of the 5-Lipoxygenase Pathway",
number = "13",
volume = "12",
doi = "10.1002/cmdc.201700309",
pages = "1081-1086"
}

Kuhnert, R., Sárosi, M., George, S., Lönnecke, P., Hofmann, B., Steinhilber, D., Murganić, B., Mijatović, S., Maksimović-Ivanić, D.,& Hey-Hawkins, E.. (2017). CarbORev-5901: The First Carborane-Based Inhibitor of the 5-Lipoxygenase Pathway. in ChemMedChem, 12(13), 1081-1086.
https://doi.org/10.1002/cmdc.201700309

Kuhnert R, Sárosi M, George S, Lönnecke P, Hofmann B, Steinhilber D, Murganić B, Mijatović S, Maksimović-Ivanić D, Hey-Hawkins E. CarbORev-5901: The First Carborane-Based Inhibitor of the 5-Lipoxygenase Pathway. in ChemMedChem. 2017;12(13):1081-1086.
doi:10.1002/cmdc.201700309 .

Kuhnert, Robert, Sárosi, Menyhárt-Botond, George, Sven, Lönnecke, Peter, Hofmann, Bettina, Steinhilber, Dieter, Murganić, Blagoje, Mijatović, Sanja, Maksimović-Ivanić, Danijela, Hey-Hawkins, Evamarie, "CarbORev-5901: The First Carborane-Based Inhibitor of the 5-Lipoxygenase Pathway" in ChemMedChem, 12, no. 13 (2017):1081-1086,
https://doi.org/10.1002/cmdc.201700309 . .